This study demonstrates network pharmacology and molecular docking assessing uncaria gambir against MCF-7 breast cancer, highlighting its multi-target capabilities.
Key Points
Uncaria gambir showed potential as an anti-cancer agent against MCF-7 breast cancer cells, with compounds like catechin and quercetin identified.
Molecular docking revealed strong affinities to target genes such as TP53 and ESR1, with binding energies ranging from -7.2 to -8.9 kcal/mol.
Active compounds were screened based on pharmacokinetic parameters, confirming their appropriate bioavailability and safety profiles.
The findings indicate that uncaria gambir could serve as a valuable source for multi-target treatments in breast cancer therapy.